Patent(s) and the Corresponding Patented Drug(s) |
Top |
World Intellectual Property Organization (WIPO) |
Patent ID |
WO2016008836 |
Title |
4,5-Diarylimidazole Derivatives As Hdac Inhibitors. |
Abstract |
The present invention relates to a 4,5-diarylimidazole derivative of formulae (I), (II) or (III): or a pharmaceutically acceptable salt thereof, wherein the 4,5-diarylimidazole derivative has a hydroxamic acid residue at a first aryl ring and a residue R1 at a second aryl ring; and wherein R1 is hydrogen, a halogen atom or an unsubstituted or substituted alkoxy group; R2 is independently selected from an unsubstituted or substituted alkyl, alkoxy or alkene group; M is a metal atom; L is a halogen atom, an unsubstituted or substituted phosphane, sulfane, arene or alkene group or a 4,5-diarylimidazole-derivative of formula (I); and n is an integer of from 1 to 5. |
Applicant(s) |
Charit Universitts Medizin Berlin |
Representative Drug(s) |
D0Z7QI |
Drug Info
|
IC50 = 28 nM |
Click to Show More |
[1] |
2
|
D0V5IQ
|
Drug Info
|
IC50 = 187 nM
|
[1] |
Patent ID |
WO2014181137 |
Title |
Novel Histone Deacetylase Inhibitors. |
Abstract |
The present invention is a compound of the formula or a pharmaceutically acceptable salt thereof. The compounds are useful as HDAC inhibitors. |
Applicant(s) |
Karus Therapeutics Ltd |
Representative Drug(s) |
D00ACL |
Drug Info
|
IC50 >= 1000 nM; IC50 <= 10000 nM |
Click to Show More |
[1] |
2
|
D00LLN
|
Drug Info
|
IC50 >= 1000 nM; IC50 <= 10000 nM
|
[1] |
3
|
D03EUD
|
Drug Info
|
IC50 >= 1000 nM; IC50 <= 10000 nM
|
[1] |
4
|
D04MVN
|
Drug Info
|
IC50 >= 1000 nM; IC50 <= 10000 nM
|
[1] |
5
|
D04VQE
|
Drug Info
|
IC50 >= 1000 nM; IC50 <= 10000 nM
|
[1] |
6
|
D08GBR
|
Drug Info
|
IC50 >= 1000 nM; IC50 <= 10000 nM
|
[1] |
7
|
D08SNJ
|
Drug Info
|
IC50 >= 1000 nM; IC50 <= 10000 nM
|
[1] |
8
|
D08XLK
|
Drug Info
|
IC50 >= 1000 nM; IC50 <= 10000 nM
|
[1] |
9
|
D08ZJZ
|
Drug Info
|
IC50 >= 1000 nM; IC50 <= 10000 nM
|
[1] |
10
|
D0BY1R
|
Drug Info
|
IC50 >= 1000 nM; IC50 <= 10000 nM
|
[1] |
11
|
D0CH4M
|
Drug Info
|
IC50 >= 1000 nM; IC50 <= 10000 nM
|
[1] |
12
|
D0DH7R
|
Drug Info
|
IC50 >= 1000 nM; IC50 <= 10000 nM
|
[1] |
13
|
D0HM6Y
|
Drug Info
|
IC50 >= 1000 nM; IC50 <= 10000 nM
|
[1] |
14
|
D0JN0A
|
Drug Info
|
IC50 >= 1000 nM; IC50 <= 10000 nM
|
[1] |
15
|
D0K2UF
|
Drug Info
|
IC50 >= 1000 nM; IC50 <= 10000 nM
|
[1] |
16
|
D0RD7T
|
Drug Info
|
IC50 >= 1000 nM; IC50 <= 10000 nM
|
[1] |
17
|
D0SF8N
|
Drug Info
|
IC50 >= 1000 nM; IC50 <= 10000 nM
|
[1] |
18
|
D0W1AX
|
Drug Info
|
IC50 >= 1000 nM; IC50 <= 10000 nM
|
[1] |
19
|
D00GLJ
|
Drug Info
|
IC50 >= 10000 nM
|
[1] |
20
|
D00XWZ
|
Drug Info
|
IC50 >= 10000 nM
|
[1] |
21
|
D01LCZ
|
Drug Info
|
IC50 >= 10000 nM
|
[1] |
22
|
D02YDG
|
Drug Info
|
IC50 >= 10000 nM
|
[1] |
23
|
D04AMI
|
Drug Info
|
IC50 >= 10000 nM
|
[1] |
24
|
D04KQU
|
Drug Info
|
IC50 >= 10000 nM
|
[1] |
25
|
D06IIL
|
Drug Info
|
IC50 >= 10000 nM
|
[1] |
26
|
D08GQL
|
Drug Info
|
IC50 >= 10000 nM
|
[1] |
27
|
D0CX1Y
|
Drug Info
|
IC50 >= 10000 nM
|
[1] |
28
|
D0E5CO
|
Drug Info
|
IC50 >= 10000 nM
|
[1] |
29
|
D0ET4U
|
Drug Info
|
IC50 >= 10000 nM
|
[1] |
30
|
D0EU5A
|
Drug Info
|
IC50 >= 10000 nM
|
[1] |
31
|
D0L3CU
|
Drug Info
|
IC50 >= 10000 nM
|
[1] |
32
|
D0M7XL
|
Drug Info
|
IC50 >= 10000 nM
|
[1] |
33
|
D0MQ2D
|
Drug Info
|
IC50 >= 10000 nM
|
[1] |
34
|
D0MR7U
|
Drug Info
|
IC50 >= 10000 nM
|
[1] |
35
|
D0N1RX
|
Drug Info
|
IC50 >= 10000 nM
|
[1] |
36
|
D0O6SJ
|
Drug Info
|
IC50 >= 10000 nM
|
[1] |
37
|
D0Q9XK
|
Drug Info
|
IC50 >= 10000 nM
|
[1] |
38
|
D0QF0Y
|
Drug Info
|
IC50 >= 10000 nM
|
[1] |
39
|
D0QN8W
|
Drug Info
|
IC50 >= 10000 nM
|
[1] |
40
|
D0S3ZB
|
Drug Info
|
IC50 >= 10000 nM
|
[1] |
41
|
D0SK9K
|
Drug Info
|
IC50 >= 10000 nM
|
[1] |
42
|
D0TH3L
|
Drug Info
|
IC50 >= 10000 nM
|
[1] |
43
|
D0TN6E
|
Drug Info
|
IC50 > 10000 nM
|
[1] |
44
|
D0YC2M
|
Drug Info
|
IC50 >= 10000 nM
|
[1] |
Patent ID |
WO2017136451 |
Title |
Hdac1/2 Inhibitors for The Treatment of Neurodegenerative and/or Cognitive Disorders. |
Abstract |
Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with HDAC activity, particularly diseases or disorders that involve activity of HDAC1 and/or HDAC2. |
Applicant(s) |
Regenacy Pharmaceuticals, Llc |
Representative Drug(s) |
D0C9NX |
Drug Info
|
IC50 = 3 nM |
[1] |
Patent ID |
WO2017053360 |
Title |
Bicyclic and Tricyclic Cap Bearing Mercaptoacetamide Derivatives As Histone Deacetylase Inhibitors. |
Abstract |
Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a peripheral neuropathy, a neurological disease, traumatic brain injury, stroke, hypertension, malaria, an autoimmune disease, autism, autism spectrum disorders, and inflammation, also are disclosed. |
Applicant(s) |
The Board of Trustes of the University of Illinois |
Representative Drug(s) |
D0F3TB |
Drug Info
|
IC50 = 13800 nM |
[1] |
Patent ID |
WO2017040564 |
Title |
Hdac Inhibitors and Therapeutic Methods Using The Same. |
Abstract |
Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a peripheral neuropathy, a neurological disease, traumatic brain injury, stroke, hypertension, malaria, an autoimmune disease, autism, autism spectrum disorders, and inflammation, also are disclosed. |
Applicant(s) |
The Board of Trustes of the University of Illinois |
Representative Drug(s) |
D0LN1T |
Drug Info
|
IC50 = 16900 nM |
[1] |
Patent ID |
WO2017039726 |
Title |
Novel Hdac Inhibitors and Methods of Treatment Using The Same. |
Abstract |
Disclosed herein are novel HDAC inhibitors. The HDAC inhibitors may be used in methods of treating cancer. The HDAC inhibitors may be used in methods of treating a neurological disorder. |
Applicant(s) |
Uwm Research Foundation, Inc |
Representative Drug(s) |
D0JB4S |
Drug Info
|
IC50 = 2.6 nM |
[1] |
Patent ID |
WO2016190630 |
Title |
Heterocyclicalkyl Derivative Compounds As Selective Histone Deacetylase Inhibitors and Pharmaceutical Compositions Comprising The Same. |
Abstract |
The present invention relates to novel heterocyclicalkyl derivatives having histone deacetylase (HDAC) inhibitory activity, optical isomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel heterocyclicalkyl derivatives. The novel heterocyclicalkyl derivatives according to the present invention are selective histone deacetylase (HDAC) inhibitors, and may be effectively used for the treatment of histone deacetylase-mediated diseases, such as cell proliferative diseases, inflammatory diseases, autosomal dominant diseases, genetic metabolic diseases, autoimmune diseases, acute/chronic neurological disease, hypertrophy, heart failure, ocular diseases, or neurodegenerative diseases. |
Applicant(s) |
Chong Kun Dang Pharmaceutical Corp |
Representative Drug(s) |
D0L7HG |
Drug Info
|
IC50 = 3840 nM |
[1] |
Patent ID |
WO2016090230 |
Title |
Pyrimidine Hydroxy Amide Compounds for Treating Peripheral Neuropathy. |
Abstract |
The invention relates to HDAC inhibitors for the treatment of peripheral neuropathy in a subject in need thereof. Also provided herein are methods for treating peripheral neuropathy in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an HDAC inhibitor. |
Applicant(s) |
Acetylon Pharmaceuticals, Inc |
Representative Drug(s) |
D0Q1QY |
Drug Info
|
IC50 = 94 nM |
[1] |
Patent ID |
WO2016067040 |
Title |
Diheteroaryl Histone Deacetylase Inhibitors and Their Use In Therapy. |
Abstract |
The present invention is a compound having the following formula: (Formula (I)) or a pharmaceutically acceptable salt thereof, wherein e.g. X is C or N; n is 1 to 10; each L is independently a 5- to 12-membered heteroaryl containing at least two nitrogen atoms; and W is a zinc-binding group. The compounds are useful as histone deacetylase (HDAC) inhibitors. |
Applicant(s) |
Karus Therapeutics Ltd |
Representative Drug(s) |
D0JR9L |
Drug Info
|
IC50 > 1000 nM |
[1] |
Patent ID |
WO2016067038 |
Title |
Polyheteroaryl Histone Deacetylase Inhibitors and Their Use In Therapy. |
Abstract |
The present invention is a compound having the following formula: or a pharmaceutically acceptable salt thereof, wherein e.g. L and Y are each independently an optionally substituted 6-membered nitrogen-containing heteroaryl; M is an optionally substituted 5- to 10-membered heteroaryl; W is a zinc-binding group; each R2 is independently hydrogen or C1-C6 alkyl; and R3 is an aryl or heteroaryl. The compounds are useful as histone deacetylase (HDAC) inhibitors. |
Applicant(s) |
Karus Therapeutics Ltd |
Representative Drug(s) |
D0LV6K |
Drug Info
|
IC50 = 500 to 1000 nM |
[1] |
Patent ID |
WO2016018795 |
Title |
Histone Deacetylase Inhibitors. |
Abstract |
Provided herein are brain penetrant histone deacetylase (HDAC) inhibitors useful for treating diseases or disorders associated with HDAC. An exemplary HDAC inhibitor provided herein exhibits a brain-to-plama ratio of 20: 1. Pharmaceutical compositions comprising HDAC inhibitors and methods for treating diseases associated with HDAC are also provided. |
Applicant(s) |
The General Hospital Corporation |
Representative Drug(s) |
D0DI9S |
Drug Info
|
IC50 = 0.3 nM |
[1] |
Patent ID |
WO2015175813 |
Title |
Heterocyclic Hydroxamic Acids As Protein Deacetylase Inhibitors and Dual Protein Deacetylase-Protein Kinase Inhibitors and Methods of Use Thereof. |
Abstract |
The present invention relates to novel hydroxamic acids which are specific histone deacetylase (HDAC) inhibitors and/or TTK/Mpsl kinase inhibitors, including pharmaceutically acceptable salts thereof, which are useful for modulating HDAC and/or TTK/Mpsl kinase activity, pharmaceutical compositions comprising these compounds, and processes for their preparation. |
Applicant(s) |
The Regents of the University of Colorado, A Body Corporate |
Representative Drug(s) |
D0BP8I |
Drug Info
|
IC50 = 23 nM |
[1] |
Patent ID |
WO2015137887 |
Title |
Fused Pyrimidine-Based Hydroxamate Derivatives. |
Abstract |
The present invention relates to fused pyrimidine-based hydroxamate compounds of formula (I), comprising a hydroxamate group, that are inhibitors of histone deacetylase (HDAC) and kinases. More particularly, the present invention relates to hydroxamate substituted purine or 5H-pyrrolo[3,2-d]pyrimidine derivatives, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of disorders/conditions/diseases involving, relating to or associated with enzymes having histone deacetylase, non-histone deacetylase and kinase activities/functions and/or via unspecified/multi-targeted mechanisms. |
Applicant(s) |
Agency for Science, Technology and Research |
Representative Drug(s) |
D0YT8O |
Drug Info
|
IC50 = 10 to 100 nM |
[1] |
Patent ID |
WO2015087151 |
Title |
Novel Azaindole Derivatives As Selective Histone Deacetylase (Hdac) Inhibitors and Pharmaceutical Compositions Comprising The Same. |
Abstract |
The present invention relates to novel azaindole derivatives, and more particularly, to novel azaindole derivatives having histone deacetylase (HDAC) inhibitory activity, isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof or solvates thereof, the use thereof for the preparation of pharmaceutical compositions, pharmaceutical compositions containing the same, a method of treating disease using the pharmaceutical compositions, and methods for preparing the novel azaindole derivatives. The novel azaindole derivatives according to the present invention are selective histone deacetylase (HDAC) inhibitors, and may be used as agents for treating malignant tumor diseases, inflammatory diseases, rheumatoid arthritis, and neurodegenerative diseases. |
Applicant(s) |
Chong Kun Dang Pharmaceutical Corp |
Representative Drug(s) |
D09PVH |
Drug Info
|
IC50 = 382 nM |
[1] |
Patent ID |
WO2015054474 |
Title |
Pyrimidine Hydroxy Amide Compounds As Histone Deacetylase Inhibitors. |
Abstract |
Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with HDAC activity, particularly diseases or disorders that involve activity of HDACl, HDAC2, and/or HDAC6. Also provided herein are methods for inhibiting migration of a neuroblastoma cell, inducing maturation of a neuroblastoma cell, and altering cell cycle progression of a neuroblastoma cell comprising administering to the cell a therapeutically effective amount of a HDACl, HDAC2, and/or HDAC6 selective inhibitor or a pharmaceutically acceptable salt thereof. |
Applicant(s) |
Acetylon Pharmaceuticals, Inc |
Representative Drug(s) |
D0EH2K |
Drug Info
|
IC50 = 21 nM |
[1] |
Patent ID |
WO2014178606 |
Title |
Novel Compounds for Selective Histone Deacetylase Inhibitors, and Pharmaceutical Composition Comprising The Same. |
Abstract |
The present invention relates to novel urea derivatives and, more particularly, to novel urea derivatives with histone deacetylase (HDAC) inhibitory activity, isomers thereof, pharmaceutically acceptable salts thereof, their use for the preparation of a medicaments comprising the same, a pharmaceutical composition comprising the same, a treatment method using the composition, and a method for preparing novel urea derivatives. The novel urea derivatives as selective histone deacetylase (HDAC) inhibitors are effective for the treatment of histone deacetylase-mediated diseases such as malignant tumors, inflammatory diseases, rheumatoid arthritis, neurodegeneration, etc. |
Applicant(s) |
Chong Kun Dang Pharmaceutical Corp |
Representative Drug(s) |
D0LP1K |
Drug Info
|
IC50 = 2120 nM |
[1] |
Patent ID |
WO2014152444 |
Title |
Histone Deacetylase Inhibitors. |
Abstract |
Proivded herein are compounds and methods for inhibiting histone deacetylase ("HDAC") enzymes (e.g., HDACl, HDAC2, and HDAC3). |
Applicant(s) |
Biomarin Pharmaceutical Inc |
Representative Drug(s) |
D0OU0J |
Drug Info
|
IC50 < 1000 nM |
[1] |
Patent ID |
WO2014143666 |
Title |
Hdac Inhibitors. |
Abstract |
Disclosed herein are compounds of formula (I), and methods of inhibiting histone deacetylase ("HDAC") enzymes (e.g., HDAC1, HDAC2, and HDAC3) using compounds of formula (I). |
Applicant(s) |
Biomarin Pharmaceutical Inc |
Representative Drug(s) |
D0UD9R |
Drug Info
|
IC50 < 1000 nM |
[1] |
Patent ID |
WO2014122222 |
Title |
Hydroxamate Derivatives Bearing Amide-Lactams As Potent Hdac Inhibitors and Their Uses As Medicaments. |
Abstract |
The present invention relates to novel amide compounds of Formula (I), and their use as anti-tumoral and pro-apoptotic agents. The invention includes the use of such compounds in medicine, in relation to cancer disease as well as other diseases where an inhibition of HDAC is responsive, and the pharmaceutical composition containing such compounds. |
Applicant(s) |
Sigma-Tau Industrie Farmaceutiche Riunite Spa |
Representative Drug(s) |
D0N2DK |
Drug Info
|
IC50 < 150 nM |
[1] |
Patent ID |
WO2014072714 |
Title |
Novel Histone Deacetylase Inhibitors and Their Use In Therapy. |
Abstract |
A compound of the formula:(I) or a pharmaceutically acceptable salt thereof, wherein: L is a 5-membered nitrogen-containing heteroaryl which is optionally fused to a benzene; Y is a 5, 6 or 7-membered nitrogen-containing heteroaryl, which is optionally fused to a benzene; and W is a zinc-binding group. The compounds are HDAC inhibitors and therefore have potential utility in therapy. |
Applicant(s) |
Karus Therapeutics Ltd |
Representative Drug(s) |
D0YD7B |
Drug Info
|
IC50 = 226 nM |
[1] |
Patent ID |
WO2013041480 |
Title |
New Thio Derivatives Bearing Lactams As Potent Hdac Inhibitors and Their Uses As Medicaments. |
Abstract |
The present invention relates to novel amide compounds of Formula (I), and their use as anti-tumoral and pro-apoptotic agents. The invention includes the use of such compounds in medicine, in relation to cancer disease as well as other diseases where an inhibition of HDAC is responsive, and the pharmaceutical composition containing such compounds. |
Applicant(s) |
Sigma-Tau Industrie Farmaceutiche Riunite Spa |
Representative Drug(s) |
D07WAT |
Drug Info
|
IC50 = 100 to 500 nM |
[1] |
Patent ID |
WO2013005049 |
Title |
N- (2 -Aminophenyl) Benzamide Derivatives As Histone Deacetylase Inhibitors. |
Abstract |
This invention relates to the discovery of novel compounds, or pharmaceutically acceptable salts thereof, which possess HDAC inhibitory activity. In particular, the compounds of the invention demonstrate selectivity towards Class I HDAC enzymes, and are accordingly expected to be useful for their anti-proliferative activity and in methods of treatment of the human or animal body, for example in preventing or inhibiting tumour growth and metastasis in cancers. The invention also relates to processes for the manufacture of the compounds defined herein, or pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an anti-proliferative effect in a warm-blooded animal such as man. |
Applicant(s) |
Cancer Research Technology Limited |
Representative Drug(s) |
D0CH8Q |
Drug Info
|
IC50 = 8700 nM |
[1] |
Patent ID |
WO2013052110 |
Title |
Novel Molecules That Selectively Inhibit Histone Deacetylase 6 Relative To Histone Deacetylase 1. |
Abstract |
The compounds of the present invention are HDAC6 selective inhibitors which are identified on the basis of accumulation of acetylated tubulin without accumulation of acetylated histones. Histone deacetylase or "HDAC" refers to enzymes capable of cleaving an acetyl group (-C(=0)CH3) from proteins, including histone and microtubulins. Compositions comprising the molecules and methods for their use to inhibit the activity of histone deacetylase, including for treatment, are also disclosed. |
Applicant(s) |
The Trustes of Columbia University In the City of New York |
Representative Drug(s) |
D0QX3G |
Drug Info
|
N.A. |
[1] |
United States Patent and Trademark Office (USPTO) |
Patent ID |
US20170044185 |
Title |
Preparation of Histone Deacetylase (Hdac) Inhibitors and Methods for Use Thereof. |
Representative Drug(s) |
D0RA0D |
Drug Info
|
IC50 = 175 nM |
[1] |
Patent ID |
US20170015655 |
Title |
Oxadiazolyl-Substituted Heterocyclic Compounds As Hdac Inhibitors and Their Preparation. |
Representative Drug(s) |
D0T7OQ |
Drug Info
|
IC50 = 1000 nM |
[1] |
Patent ID |
US20130267542 |
Title |
Preparation of Substituted Quinazolinones As Histone Deacetylases (Hdacs) Inhibitors. |
Representative Drug(s) |
D0ZG5X |
Drug Info
|
IC50 >= 10000 nM |
[1] |